Anemia
The 19th European Association for Haemophilia and Allied Disorders (EAHAD) Annual Congress, held in Dublin from 3-6 February 2026, showcased many exciting novel advancements in haemophilia care. Below, learn more about the highly anticipated late-breaking abstracts, showcasing fresh, innovative thinking that ...
The 67th ASH Annual Meeting and Exposition brought over 30,000+ attendees, 5,000+ novel abstracts and 275+ exhibitors corporate supporters, academic leaders and patient-advocacy groups. The meeting highlighted innovations ranging from novel agents to real-world evidence and patient-centred care. In this article, hear from the experts on the key breakthroughs and clinical insights set to shape the future of haematology practice.
The 67th ASH Annual Meeting and Exposition spotlighted many pivotal trial results across non-malignant haematology including immune thrombocytopenia, bleeding disorders, iron deficiency, von Willebrand disease, cancer-associated hematologic complications and more. We break down some of the most important abstracts presented, and what this might mean for future clinical practice.
A leading expert on sleep and shift work, Grace explores how disrupted sleep affects physician health in both the short and long term, as well as its impact on safety and performance. We also discuss what this means for patient outcomes and share practical strategies to manage sleep loss.
As part of touchHAEMATOLOGY Future Leaders 2025, Dr Simona Maria Di Modica shares the inspirations, discoveries, and future directions that shape her work at the intersection of iron metabolism and erythropoiesis.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
Nurses account for the largest group of professionals in the healthcare system and there are an estimated 29 million nurses worldwide (WHO, 2024). Nursing practice needs to be dynamic in order to respond to the changing needs of an aging population and ...
The American Society of Hematology (ASH) held its 66th Annual Meeting from 7–10 December 2024. Among the highlights of the meeting were six late-breaking abstracts that have the potential to influence how healthcare professionals approach a range of condition,s from introducing ...
Françoise Bernaudin (Intercommunal Hospital of Créteil, Créteil, France) joins touchHAEMATOLOGY to discuss the DREPAGREFFE-1 (NCT01340404) and DREPAGREFFE-2 trials (NCT 05053932). DREPAGREFFE-1 was the first prospective study to compare allogeneic stem cell transplantation (alloSCT) with standard-of-care (SoC) for children ...
Françoise Bernaudin (Intercommunal Hospital of Créteil, Créteil, France) joins touchHAEMATOLOGY to discuss the main challenges in implementing alloSCT as a treatment for sickle cell anaemia in children, particularly with significant disparities in access to curative treatments like ...
Cold agglutinin disease (CAD) is a rare haemolytic anaemia that causes fatigue, chronic inflammation and thromboembolic complications. Until recently, no therapies have been approved for CAD. Off-label rituximab – a B-cell depleting antibody – induces a short-lived partial response in around half ...
In the burgeoning age of personalized medicine, the treatment of rare anaemias is being transformed from one relying on transfusions and general immunosuppressants to one targeting the underlying disease pathology. Rare anaemias currently experiencing this shift include the autoimmune haemolytic ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
